Home > Resources > Whitepapers > Expediting drug approval

Expediting drug approval

In recent years, FDA has made great advances in the review of new drugs. From 2012 to 2015, FDA approved a record number of marketing applications for novel drugs, averaging 38 approved products per year. In 2016, FDA approved only 22 novel drugs but the percentage of applications leveraging an expedited program was at its highest.

I'm For Real

Enter your details once to access all our information and resources

Spotlight

Meissa Vaccines

Meissa Vaccines is a private biotech company focused on the advancement of vaccines for respiratory syncytial virus (RSV), the largest unmet respiratory medical need in pediatrics, and rhinovirus, the leading cause of infectious disease worldwide. The company is also developing vaccines for parainfluenza and human metapneumovirus. Meissa Vaccines was founded on proprietary technologies employing synthetic biologic and reverse genetics to create safer, more effective vaccines. The technology is exclusively licensed from Dr. Martin Moore's laboratory at Emory University. Dr. Moore, together with Dr. Roderick Tang, a leading developer of viral vaccines, co-founded Meissa.

OTHER WHITEPAPERS
news image

New technology advances biopharma chromatography productivity

whitePaper | February 16, 2023

Monoclonal antibody drugs (mAbs) make up more than 50 percent of the biologics on the market today, as well as a significant number of new drugs in the development pipeline. The value and impact of these therapies has been dramatic.

Read More
news image

Alcami Grows Contract Manufacturing and Laboratory Business 20%

whitePaper | February 23, 2023

A period of substantial growth is an exciting time in the life of any company. For those in pharmaceutical contract research, development, or manufacturing.

Read More
news image

Overcoming The Challenges of Pediatric Formulation

whitePaper | February 15, 2023

Pediatric populations represent the most diverse patient groups in all of medicine. Factors such as individual preferences, physiology, and dosage considerations all serve to complicate drug formulation aimed at pediatric care.

Read More
news image

Understanding Net Pharmaceutical Expenditure Dynamics in Europe

whitePaper | April 12, 2022

The level of pharmaceutical expenditure is closely watched and often commented upon, but the composition of that expenditure and its dynamics are not as well understood.

Read More
news image

Research and Development in the Pharmaceutical Industry

whitePaper | April 1, 2021

Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.

Read More
news image

The Key to Commercializing Revolutionary Gene Therapiesand Other Orphan Drugs

whitePaper | October 27, 2022

In today’s evolving, value-based environment for specialty drugs, hightouch services that enhance patient outcomes are playing an increasingly important role in market access and patient care delivery

Read More

New technology advances biopharma chromatography productivity

whitePaper | February 16, 2023

Monoclonal antibody drugs (mAbs) make up more than 50 percent of the biologics on the market today, as well as a significant number of new drugs in the development pipeline. The value and impact of these therapies has been dramatic.

Read More

Alcami Grows Contract Manufacturing and Laboratory Business 20%

whitePaper | February 23, 2023

A period of substantial growth is an exciting time in the life of any company. For those in pharmaceutical contract research, development, or manufacturing.

Read More

Overcoming The Challenges of Pediatric Formulation

whitePaper | February 15, 2023

Pediatric populations represent the most diverse patient groups in all of medicine. Factors such as individual preferences, physiology, and dosage considerations all serve to complicate drug formulation aimed at pediatric care.

Read More

Understanding Net Pharmaceutical Expenditure Dynamics in Europe

whitePaper | April 12, 2022

The level of pharmaceutical expenditure is closely watched and often commented upon, but the composition of that expenditure and its dynamics are not as well understood.

Read More

Research and Development in the Pharmaceutical Industry

whitePaper | April 1, 2021

Every year, the U.S. pharmaceutical industry develops
a variety of new drugs that provide valuable medical
benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and
the federal government. Policymakers have considered
policies that would lower drug prices and reduce federal
drug expenditures. Such policies would probably reduce
the industry’s incentive to develop new drugs.

Read More

The Key to Commercializing Revolutionary Gene Therapiesand Other Orphan Drugs

whitePaper | October 27, 2022

In today’s evolving, value-based environment for specialty drugs, hightouch services that enhance patient outcomes are playing an increasingly important role in market access and patient care delivery

Read More
More Whitepapers

Spotlight

Meissa Vaccines

Meissa Vaccines is a private biotech company focused on the advancement of vaccines for respiratory syncytial virus (RSV), the largest unmet respiratory medical need in pediatrics, and rhinovirus, the leading cause of infectious disease worldwide. The company is also developing vaccines for parainfluenza and human metapneumovirus. Meissa Vaccines was founded on proprietary technologies employing synthetic biologic and reverse genetics to create safer, more effective vaccines. The technology is exclusively licensed from Dr. Martin Moore's laboratory at Emory University. Dr. Moore, together with Dr. Roderick Tang, a leading developer of viral vaccines, co-founded Meissa.

Events